SinoMab BioScience (3681) Fundamentals 2026 — Revenue Analysis | SniperIQ
SinoMab BioScience (3681) is a HK-listed Healthcare company in Biotechnology with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SinoMab BioScience's market cap?
SinoMab BioScience (3681) has a market capitalization of approximately HK
What is SinoMab BioScience's P/E ratio?
SinoMab BioScience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SinoMab BioScience?
SinoMab BioScience runs a net profit margin of -1063.8%, a gross margin of 100.0%, and an operating margin of -1296.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does SinoMab BioScience pay a dividend?
SinoMab BioScience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SinoMab BioScience financially healthy?
SinoMab BioScience carries a debt-to-equity ratio of 0.67x and a current ratio of 1.91x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SinoMab BioScience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SinoMab BioScience (3681) the key facts are: market cap HK
Track SinoMab BioScience's full fundamentals live
Get SinoMab BioScience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.